https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=70&w=70

msapplication-square70x70logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=150&w=150

msapplication-square150x150logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=310&w=310

msapplication-square310x310logo

https://www.datocms-assets.com/40598/1620069893-ecpfavicon300x300.png?h=150&w=310

msapplication-square310x150logo

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our <a href="https://www.wsgr.com/en/privacy-policy.html" target="_blank">privacy policy</a>.

Aviation

Biotech

Blockchain and Cryptocurrency

Clean Technology

Communications and Networking

Consumer Products and Services

Data Storage and Cloud

Digital Health

Digital Media and Entertainment

Electronic Gaming

Energy

Financial Services

Fintech

FoodTech and AgTech

Global Generics

Internet

Life Sciences

Medical Devices

Mobile Devices

Mobility

Semiconductors

Software

Wilson Sonsini is pleased to support the LaunchBio Larger Than Life Sciences Series:&nbsp;Funding Fundamentals Part 1, Early Stage Strategies. The more an early-stage company knows about funding, the more successful they are going to be. Funding an early-stage life science startup is a challenging task. And the rules have changed in the past year! Adaptation is critical and learning how to virtually connect to the right investors is paramount. A panel of experts and VCs will share insights on new funds and financing trends, mistakes to avoid leading up to financing, and everything founders need to know about a term sheet.

James

LaunchBio Larger Than Life Science: Funding Fundamentals Part 1 - Early Stage Strategies

Wilson Sonsini is pleased to support the LaunchBio Larger Than Life Sciences Series:&nbsp;Compensation Confidential. This special edition of&nbsp;Compensation Confidential&nbsp;will highlight national, regional and market-level data from the nation&rsquo;s leading life science hubs. Drawing on new data from the&nbsp;2021 Private Company Compensation Survey&nbsp;the latest insights and analysis into compensation for US biotech and life sciences private companies will be covered. Panelists will review trends in base pay, bonuses, total cash and founder/non-founder equity. The conversation will include practical information for founders on how to navigate legal and financial planning issues pre-exit and answer questions about how companies are planning on compensating remote employees and creating plans for returning to the office.

LaunchBio Larger Than Life Science: Compensation Confidential

Innovative and passionate; that&#39;s how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.

Our **Industry** Coverage

BioTech Industry

Illumina Completes IPO Worth $96 Million

Genentech Acquired by Roche for $46.8 Billion

Pacific Biosciences Raises $200 Million in IPO

Xenon Pharmaceuticals Launches IPO

BioCardia Unveils Reverse Merger

Denali Therapeutics Makes Record BioTech IPO

WuXi AppTec Raises $356 Million IPO

Applied Molecular Transport Closes IPO at $154 Million

Industry Highlights

**Celebrating** our
**founders'** **successes**

Attorneys

**focused**
on **this**
**industry**

events

we **organize**
**for** you

recent news

we want to **share**
**with you**

other industries

we have **covered**

Our Industry Coverage

Celebrating our
founders’ successes

BioTech Industry

2000

Illumina Completes IPO Worth $96 Million

2009

Genentech Acquired by Roche for $46.8 Billion

2010

Pacific Biosciences Raises $200 Million in IPO

2014

Xenon Pharmaceuticals Launches IPO

2016

BioCardia Unveils Reverse Merger

2017

Denali Therapeutics Makes Record BioTech IPO

2018

WuXi AppTec Raises $356 Million IPO

2020

Applied Molecular Transport Closes IPO at $154 Million

Attorneys

focused
on this
industry

Megan
Baier

Jennifer
Fang

Kathy
Ku

Martin
Waters

Josh
Beser

Chris
Fennell

Michael
Nordtvedt

Zachary
Myers

Bryan
King

Philip
Oettinger

recent news

we want to share
with you

Firm Advises ARS Pharmaceuticals on IP Matters Related to $55 Million Series D

Wilson Sonsini Advises SR One on ARS Pharmaceuticals’ $55 Million Series D

Wilson Sonsini Advises DiCE Molecules on Patent Matters Related to $60 Million Series C and IPO Filing

Wilson Sonsini Advises RA Capital on PepGen’s $112.5 Million Financing

other industries

we have covered

.css-vurnku{box-sizing:border-box;margin:0;min-width:0;}Our Industry Coverage

Celebrating ourfounders’ successes

2000

Illumina Completes IPO Worth $96 Million

2009

Genentech Acquired by Roche for $46.8 Billion

2010

Pacific Biosciences Raises $200 Million in IPO

2014

Xenon Pharmaceuticals Launches IPO

2016

BioCardia Unveils Reverse Merger

2017

Denali Therapeutics Makes Record BioTech IPO

2018

WuXi AppTec Raises $356 Million IPO

2020

Applied Molecular Transport Closes IPO at $154 Million

Attorneys

focusedon thisindustry

Megan Baier

Jennifer Fang

Kathy Ku

Martin Waters

Josh Beser

Chris Fennell

Michael Nordtvedt

Zachary Myers

Bryan King

Philip Oettinger

recent news

we want to sharewith you

Firm Advises ARS Pharmaceuticals on IP Matters Related to $55 Million Series D

Wilson Sonsini Advises SR One on ARS Pharmaceuticals’ $55 Million Series D

Wilson Sonsini Advises DiCE Molecules on Patent Matters Related to $60 Million Series C and IPO Filing

Wilson Sonsini Advises RA Capital on PepGen’s $112.5 Million Financing

other industries

we have covered

Our Industry Coverage

Celebrating our
founders’ successes

focused
on this
industry

Megan
Baier

Jennifer
Fang

Kathy
Ku

Martin
Waters

Josh
Beser

Chris
Fennell

Michael
Nordtvedt

Zachary
Myers

Bryan
King

Philip
Oettinger

we want to share
with you